Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency.
Human-human B cell hybridomas constructed from B lymphocytes of common variable immunodeficiency (CVI) patients and the nonsecreting cell line WIL2/729 HF consistently secrete low levels of Ig and appear to retain a defect characteristic of the CVI patient's B cells. We assessed the differentiative capacity of retinoic acid (RA) on these hybridomas, as well as on hybridomas constructed from normal B cells and from patients with selective IgA deficiency. RA at concentrations varying between 10(-5) and 10(-9) M augmented IgM secretion 4-20-fold from four of four CVI hybridomas tested, but did not affect Ig secretion from normal or IgA-deficiency hybridomas. In support of this elevated Ig secretion, RA enhanced the de novo synthesis of biosynthetically labeled light (kappa) and heavy (mu) Ig (up to 4- and 15-fold, respectively) in the CVI hybridoma line JK32.1. The increase in IgM synthesis/secretion could not be accounted for by RA-induced alteration in the cell cycle. In inducing this increase in IgM production, RA was found to affect two aspects of Ig gene expression: (a) the steady-state levels of heavy and light chain mRNAs were enhanced, and (b) the processing of mu heavy chain transcripts to the secreted mRNA form became favored over the membrane mRNA form. We also show that expression of Leu-17 (CD38), a surface marker that is re-expressed in the late pre-plasma stage of B cell development, was increased by RA from less than 20% to greater than 90% of the total cell population, with a concomitant 4-10-fold augmentation in the mean fluorescence intensity. Changes in both Leu-17 expression and de novo Ig synthesis were prominent by 24 h, but could be observed as early as 8 h after induction. Taken together, our study demonstrates that RA affects a marked alteration in the differentiated state of the CVI hybridoma clones. This finding suggests that retinoids can enhance the functional capabilities of B cells with defects in maturation and support further studies to evaluate their clinical potential in CVI.
Sherr
E
E
Department of Medicine, UCLA School of Medicine 90024.
Adelman
D C
DC
Saxon
A
A
Gilly
M
M
Wall
R
R
Sidell
N
N
D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D002453:Cell Cycle; D002454:Cell Differentiation / Q000187:drug effects; D006651:Histocytochemistry; D006801:Humans; D006825:Hybridomas / Q000276:immunology / Q000473:pathology*; D017098:IgA Deficiency; D007124:Immunoenzyme Techniques; D007075:Immunoglobulin M / Q000096:biosynthesis / Q000378:metabolism; D007136:Immunoglobulins / Q000235:genetics / Q000378:metabolism; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000473:pathology*; D010641:Phenotype; D012333:RNA, Messenger / Q000096:biosynthesis; D014212:Tretinoin / Q000494:pharmacology*
D007075:Immunoglobulin M; D007136:Immunoglobulins; D012333:RNA, Messenger; D014212:Tretinoin